Press coverage about Pluristem Therapeutics (NASDAQ:PSTI) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Pluristem Therapeutics earned a daily sentiment score of 0.10 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 44.6377550126265 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Several brokerages have recently issued reports on PSTI. ValuEngine upgraded Pluristem Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Wednesday, May 2nd. HC Wainwright set a $4.00 price target on Pluristem Therapeutics and gave the company a “buy” rating in a research note on Friday, May 11th. Maxim Group set a $3.00 price target on Pluristem Therapeutics and gave the company a “buy” rating in a research note on Thursday, May 10th. Zacks Investment Research upgraded Pluristem Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, July 12th. Finally, B. Riley began coverage on Pluristem Therapeutics in a research note on Tuesday, July 31st. They issued a “buy” rating and a $4.50 price target on the stock. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $3.60.
Shares of Pluristem Therapeutics remained flat at $$1.26 during mid-day trading on Friday, according to Marketbeat Ratings. The company had a trading volume of 144,089 shares, compared to its average volume of 172,767. Pluristem Therapeutics has a 12 month low of $1.09 and a 12 month high of $2.12. The firm has a market cap of $138.59 million, a P/E ratio of -3.92 and a beta of 0.32.
Pluristem Therapeutics (NASDAQ:PSTI) last released its quarterly earnings data on Thursday, May 10th. The biotechnology company reported ($0.01) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.08. equities analysts expect that Pluristem Therapeutics will post -0.24 EPS for the current fiscal year.
About Pluristem Therapeutics
Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.
See Also: Leveraged Buyout (LBO) Explained
Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.